Merck is undergoing a strategic restructuring, resulting in immediate job cuts in administration, sales, and research as part of a plan to save $3 billion by 2027.

The program was formally launched July 28 at a signing ceremony at Wake Tech’s Beltline Education Center in Raleigh. Leaders ...

The drugmaker has invested $10 billion in Wake and Durham counties over the past 30 years. Biogen says that figure will ...

Trump has rolled back many of his steepest tariffs over recent months, including a sky-high levy on China, the top source of ...

Merck & Company, Inc. (NYSE:MRK) is one of the high-margin pharma stocks to buy now. Jefferies has raised its price target on Merck & Co. (NYSE: MRK) to $141 from $138 while maintaining a Buy ...

Merck to acquire Verona Pharma for $10B, gaining Ohtuvayre, a breakthrough COPD treatment with rapid uptake since its 2024 launch.

Merck’s potential for upside hinges on its ability to execute on several key fronts: successfully advancing its pipeline, expanding geographically, and making strategic acquisitions.

Merck remains a top Big Pharma name with strong leadership, rising sales, and high margins, despite regulatory fears and pressures. Learn why MRK stock is a buy.

In this analysis, we explore the potential upside for Merck despite its short-term hurdles.

Merck's Keytruda receives FDA approval for head and neck cancer after showing improved event-free survival in Phase 3 KEYNOTE-689 trial.

Merck has received approval from the Food and Drug Administration to expand use of its blockbuster drug, Keytruda, to treat head and neck cancers.